Objectives: To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resistance mutations in HCV genotype 1-infected PI-naive individuals in Italy.
Introduction
The hepatitis C virus (HCV) NS3/4A protease is the target of several macrocyclic and linear inhibitors. 1 Compared with the pegylated interferon plus ribavirin standard of care (SOC), the SOC plus either of the first two approved linear inhibitors, telaprevir and boceprevir, was more effective in HCV genotype 1-infected subjects. 2 However, in vitro and in vivo studies have documented boceprevir/telaprevir-driven selection of unique mutations and cross-resistant mutations in the NS3 protease catalytic domain. 3 This is leading to a paradigm shift in the monitoring of HCV treatment because selection of resistant variants has not been an issue with the pegylated interferon plus ribavirin treatment. Along with the definition of HCV mutations associated with decreased susceptibility to the different protease inhibitors (PIs), sequence analysis of the HCV NS3 genome region may become an integral part of the management of patients who are under treatment or are candidates for treatment. In this study we investigated the prevalence of HCV NS3 amino acid changes provisionally included among the NS3/NS4A inhibitor resistance-associated mutations in a group of HCV-infected subjects living in Italy and not previously treated with PIs. Amplification and sequencing of the NS3 region Viral RNA was extracted from plasma samples using the QIAamp Viral RNA MiniKit (Qiagen, Hamburg, Germany). A 2835 bp DNA fragment encompassing the whole NS3/4A region (coordinates 2640-5474 of the H77 HCV genome, GenBank accession number AF009606) was obtained by random hexamer-driven reverse transcription followed by a heminested PCR. Primers P519Fwd (5 ′ -TCCTTCCTYGTGTTCTTCTG-3 ′ ) and P520Rev (5 ′ -GCCTTCTGYTTGAAYTGCTC-3 ′ ) were used in the first 30-cycle PCR and primers P523Rev (5 ′ -GCACTCYTCCATCTCATCGAA-3 ′ ) and P519Fwd were used in the second 35-cycle PCR. Bidirectional DNA sequencing was performed using the BigDye w Terminator v3.1 Cycle Sequencing Kit (Life Technologies Corporation, Carlsbad, CA, USA) with five different primers spanning the whole NS3 region: P525Fwd
Patients and methods

Patients
. NS3 sequences were aligned with genotype 1a, 1b and 1c reference sequences obtained from the Los Alamos HCV Sequence Database (http://hcv.lanl.gov/content/index). A phylogenetic tree was constructed by the neighbour-joining method using the PHYLIP software package version 3.69 (http://evolution.genetics.washington.edu/phylip.html) and edited with FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/software/ figtree/). Sequences were submitted to GenBank under accession numbers JN704192 to JN704300.
Scoring of PI resistance mutations
In the absence of a universally accepted reference list for HCV PI resistance mutations, a comprehensive list of linear and macrocyclic PI resistance mutations was derived by combining the lists recently published by Kieffer et al., 5 Soriano et al. 1 and Halfon and Locarnini. 
Results
The median (IQR) age at testing was 48 (44 -52) years and 59.8% of the patients were males. The median (IQR) HCV viral load was 6.03 (5.58 -6.61) log IU/mL. NS3 amplification and sequencing was successful with 109 (97.3%) samples, the three failures not being associated with low-level viraemia (data not shown). Phylogenetic analysis identified 67 and 42 NS3 sequences as belonging to genotype 1a and 1b, respectively. HIV-coinfected patients were more likely to harbour genotype 1a than HCV-monoinfected patients (50/64 versus 17/45; P,0.0001, Fisher's exact test). Genotype 1a sequences clustered within two different sub-clades of similar size (Figure 1 ). Of note, there were 10 of 62 (16.1%) cases in which the original subtype assignment by LiPA was not confirmed by NS3 sequencing: one 1a was genotyped as 1b in NS3 and nine 1b were genotyped as 1a in NS3. By contrast, all the genotype assignments based on 5 ′ UTR plus partial core sequencing were concordant with those obtained by NS3 sequencing.
Overall, NS3 mutations associated with resistance to boceprevir, telaprevir or macrocyclic PIs were scored in 21 (19.3%) cases (Table 1) . There was no significant association between HCV PI resistance mutations and HIV coinfection. Likewise, exposure to HIV PIs in the HIV-coinfected patient population was not associated with HCV PI resistance mutations, detected in 9/52 (17.3%) of the HIV PI-exposed patients and in 2/12 (16.7%) of the HIV-positive HIV PI-naive patients. The most common mutation was Q80K, included in the macrocyclic PI but not in the boceprevir and/or telaprevir resistance lists. Interestingly, this mutation was detected only in genotype 1a sequences (11/67 in genotype 1a versus 0/42 in genotype 1b; P ¼ 0.006, Fisher's exact test). By contrast, the other PI resistance mutations found were all related to boceprevir and telaprevir, but not macrocyclic PIs, and were evenly distributed in genotypes 1a and 1b. Only one viral strain had two resistance mutations (V36L and T54S).
Discussion
The HCV NS3 genotyping system presented was very effective, failing to amplify only 2.7% of the samples analysed. Full-length sequencing of the NS3 region may also make it possible to obtain genotype and subtype information with increased reliability with respect to hybridization assays such as LiPA. 6 We indeed observed 16.1% of cases in which LiPA and phylogenetic analysis of the NS3 sequence yielded a different subtype; in particular, several 1b genotypes by LiPA were classified as 1a by NS3 sequencing. Complete NS3 sequencing also made it possible to discern two different lineages or sub-subtypes within genotype 1a, as recently reported in a full-genome sequence study. 7 It is presently unknown whether this distinction has any relevance in the setting of clinical use of NS3/4A PI therapy.
Using a combined list of NS3/4A PI resistance mutations as a reference, as many as 19.3% of patients harboured a prevalent virus population with at least one NS3/4A PI resistance mutation. However, all but one case had just one mutation and half of the cases had only Q80K, so far documented to confer resistance to only one macrocyclic PI (TMC435350). 3 Nevertheless, the strong association of this mutation with genotype 1a, reported also in another study, 8 may discourage the use of this compound in patients infected with this HCV sub-genotype. Thus, mutations associated with resistance to the currently licensed HCV PIs boceprevir and telaprevir (V36L, T54S and V55A) were detected in only 10 (9.2%) of the patients included in this study. With respect to other reports, we found a larger percentage of patients harbouring a prevalent virus population with the V36L mutation (5.5% versus 0.9% -1.6%).
9 -12 Unlike our study, some reports have documented the occurrence of V36L 10 or T54S 11 only in HCV genotype 1a-infected patients. However, the small number of cases and the uncertainty of subtype assignment by different methods do not allow at present the establishment of significant subtype specificity for these and other naturally occurring boceprevir/telaprevir resistance mutations. It must be noted that the most important boceprevir/telaprevir resistance mutations (V36A/M, T54A, R155K, A156S/T/V and V170A) 3 were not detected. Clearly, the question remains whether and which baseline HCV species carrying drug resistance-related mutations have a significant impact on Natural variability of HCV NS3/4A response to NS3/4A inhibitor treatment. While the use of PIs is established as an SOC in HCV-infected patients, analysing the evolution of the target region in the HCV genome is warranted in order to disclose the role of HCV drug resistance and provide the most convenient virological monitoring for patients who are candidates for treatment or are under treatment. Natural variability of HCV NS3/4A
